Olpasiran vs SYH2068
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: LPA gene / apolipoprotein(a) mRNA · full Atherosclerotic Cardiovascular Disease pipeline
Olpasiran
Developed by Amgen and partners
NCT04270760 · Phase 2 · completed
The study randomly assigned 281 participants to four olpasiran regimens or placebo, with participants and investigators blinded. All four olpasiran groups significantly reduced the primary endpoint, percentage change in Lp(a) at week 36, versus placebo (all adjusted p<0.001), but this biomarker endpoint provides more limited evidence than a clinical cardiovascular outcome.
Next expected readout: March 2028 · NCT05581303 (registry estimate)
Reported efficacy
Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W) (met)
Result source: NCT04270760
SYH2068
Developed by CSPC Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT07640217 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olpasiran | SYH2068 |
|---|---|---|
| LDL-C, % change | -17.3% vs 10.1%−27.4 vs placeboNCT042707607 other results
| —Not reported |
| Non-HDL-C, % change | —Trial running · NCT07293260 | —Not reported |
| ApoB, % change | -7.2% vs 12.3%−19.5 vs placeboNCT042707607 other results
| —Not reported |
| Lp(a), % change | -97.5% vs 3.6%−101.1 vs placeboNCT04270760133 other results
| —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT07293260 | —Not reported |
LDL-C, % change
- Olpasiran
- -17.3% vs 10.1%−27.4 vs placeboNCT04270760
7 other results
- -16.9% vs 10.1% NCT04270760
- -16.7% vs 6.2% NCT04270760
- -18.5% vs 6.2% NCT04270760
- -11.5% vs 10.1% NCT04270760
- -16.3% vs 6.2% NCT04270760
- -14.7% vs 10.1% NCT04270760
- -17.4% vs 6.2% NCT04270760
- SYH2068
- —Not reported
Non-HDL-C, % change
- Olpasiran
- —Trial running · NCT07293260
- SYH2068
- —Not reported
ApoB, % change
- Olpasiran
- -7.2% vs 12.3%−19.5 vs placeboNCT04270760
7 other results
- -9.5% vs 12.3% NCT04270760
- -10.2% vs 7.4% NCT04270760
- -11.4% vs 7.4% NCT04270760
- -4.8% vs 12.3% NCT04270760
- -9.3% vs 7.4% NCT04270760
- -7.7% vs 12.3% NCT04270760
- -11.5% vs 7.4% NCT04270760
- SYH2068
- —Not reported
Lp(a), % change
- Olpasiran
- -97.5% vs 3.6%−101.1 vs placeboNCT04270760
133 other results
- -96.9% vs 3.6% NCT04270760
- -93.8% vs 3.6% NCT04270760
- -66.9% vs 3.6% NCT04270760
- -97.3% vs 3.6% NCT04270760
- -82.4% vs 3.6% NCT04270760
- -92.5% vs 3.6% NCT04270760
- -64.9% vs 3.6% NCT04270760
- -56.5% vs -19.3% NCT03626662
- -66.0% vs -26.7% NCT03626662
- -72.3% vs -31.5% NCT03626662
- -75.2% vs -23.8% NCT03626662
- -80.2% vs -24.9% NCT03626662
- -86.7% vs -4.9% NCT03626662
- -93.4% vs -22.3% NCT03626662
- -95.8% vs -15.2% NCT03626662
- -98.0% vs 3.4% NCT03626662
- -98.8% vs 1.3% NCT03626662
- -99.0% vs 1.3% NCT03626662
- -98.5% vs -6.5% NCT03626662
- -95.9% vs -1.6% NCT03626662
- -81.2% vs -1.6% NCT03626662
- -53.1% vs 0.7% NCT03626662
- -30.3% vs 11.5% NCT03626662
- -16.0% vs 8.4% NCT03626662
- -46.3% vs -19.3% NCT03626662
- -52.1% vs -26.7% NCT03626662
- -59.6% vs -31.5% NCT03626662
- -64.7% vs -23.8% NCT03626662
- -76.6% vs -24.9% NCT03626662
- -81.9% vs -4.9% NCT03626662
- -73.7% vs -4.9% NCT03626662
- -85.4% vs -22.3% NCT03626662
- -85.4% vs -22.3% NCT03626662
- -88.4% vs -15.2% NCT03626662
- -89.2% vs -15.2% NCT03626662
- -93.9% vs 3.4% NCT03626662
- -96.4% vs 3.4% NCT03626662
- -95.5% vs 1.3% NCT03626662
- -98.3% vs 1.3% NCT03626662
- -96.3% vs -1.5% NCT03626662
- -96.7% vs 1.3% NCT03626662
- -98.5% vs 1.3% NCT03626662
- -96.4% vs -6.5% NCT03626662
- -98.2% vs -6.5% NCT03626662
- -92.1% vs -1.6% NCT03626662
- -95.4% vs -1.6% NCT03626662
- -87.1% vs -3.1% NCT03626662
- -84.1% vs -6.0% NCT03626662
- -69.1% vs -1.6% NCT03626662
- -82.7% vs -1.6% NCT03626662
- -46.7% vs 0.7% NCT03626662
- -58.2% vs 0.7% NCT03626662
- -8.4% vs 11.5% NCT03626662
- -34.6% vs 11.5% NCT03626662
- -4.0% vs 8.4% NCT03626662
- -21.6% vs 8.4% NCT03626662
- -73.5% vs -4.9% NCT03626662
- -51.7% vs -4.9% NCT03626662
- -77.0% vs -22.3% NCT03626662
- -60.2% vs -22.3% NCT03626662
- -86.4% vs -15.2% NCT03626662
- -68.5% vs -15.2% NCT03626662
- -91.4% vs 3.4% NCT03626662
- -80.5% vs 3.4% NCT03626662
- -94.7% vs 1.3% NCT03626662
- -87.3% vs 1.3% NCT03626662
- -95.4% vs -1.5% NCT03626662
- -96.0% vs 1.3% NCT03626662
- -91.2% vs 1.3% NCT03626662
- -95.8% vs -6.5% NCT03626662
- -89.6% vs -6.5% NCT03626662
- -92.6% vs -1.6% NCT03626662
- -85.4% vs -1.6% NCT03626662
- -87.8% vs -3.1% NCT03626662
- -81.2% vs -6.0% NCT03626662
- -72.5% vs -1.6% NCT03626662
- -66.7% vs -1.6% NCT03626662
- -34.4% vs 0.7% NCT03626662
- -31.0% vs 0.7% NCT03626662
- -17.2% vs 11.5% NCT03626662
- -13.4% vs 11.5% NCT03626662
- 1.4% vs 8.4% NCT03626662
- -2.1% vs 8.4% NCT03626662
- -84.3% vs -4.9% NCT03626662
- -56.6% vs -15.2% NCT03626662
- -79.9% vs 3.4% NCT03626662
- -83.6% vs 1.3% NCT03626662
- -86.9% vs -1.5% NCT03626662
- -88.5% vs 1.3% NCT03626662
- -88.6% vs -6.5% NCT03626662
- -85.0% vs -1.6% NCT03626662
- -79.2% vs -3.1% NCT03626662
- -76.3% vs -6.0% NCT03626662
- -65% vs -1.6% NCT03626662
- -34.0% vs 0.7% NCT03626662
- 2.5% vs 11.5% NCT03626662
- 8.3% vs 8.4% NCT03626662
- -32.2% vs -4.9% NCT03626662
- -41.8% vs -22.3% NCT03626662
- -50.3% vs -15.2% NCT03626662
- -82.1% vs 3.4% NCT03626662
- -61.5% vs 3.4% NCT03626662
- -88.9% vs 1.3% NCT03626662
- -70.5% vs 1.3% NCT03626662
- -90.0% vs -1.5% NCT03626662
- -87.4% vs 1.3% NCT03626662
- -76.2% vs 1.3% NCT03626662
- -88.8% vs -6.5% NCT03626662
- -75.4% vs -6.5% NCT03626662
- -85.8% vs -1.6% NCT03626662
- -72.2% vs -1.6% NCT03626662
- -77.1% vs -3.1% NCT03626662
- -69.6% vs -6.0% NCT03626662
- -62.0% vs -1.6% NCT03626662
- -53.1% vs -1.6% NCT03626662
- -30.1% vs 0.7% NCT03626662
- -29.5% vs 0.7% NCT03626662
- -6.5% vs 11.5% NCT03626662
- -12.8% vs 11.5% NCT03626662
- -1.1% vs 8.4% NCT03626662
- -1.6% vs 8.4% NCT03626662
- -49.9% vs 3.4% NCT03626662
- -59.4% vs 1.3% NCT03626662
- -67.8% vs -1.5% NCT03626662
- -70.2% vs 1.3% NCT03626662
- -72.1% vs -6.5% NCT03626662
- -65.8% vs -1.6% NCT03626662
- -62.3% vs -3.1% NCT03626662
- -56.8% vs -6.0% NCT03626662
- -46.8% vs -1.6% NCT03626662
- -18.0% vs 0.7% NCT03626662
- -9.6% vs 11.5% NCT03626662
- -13.9% vs 8.4% NCT03626662
- SYH2068
- —Not reported
3-point MACE (% with event)
- Olpasiran
- —Trial running · NCT07293260
- SYH2068
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SYH2068: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Olpasiran: 3 of 4 rows · SYH2068: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olpasiran |
|---|---|
| Dropout rate | 7.1%225 mg Q12Wa NCT04270760 · Phase 2 show 22 more results—225 mg Q12W NCT04270760 · Phase 2 —225 mg Q12W NCT04270760 · Phase 2 0%225 mg Q24W NCT04270760 · Phase 2 —225 mg Q24W NCT04270760 · Phase 2 —225 mg Q24W NCT04270760 · Phase 2 5.2%75 mg Q12W NCT04270760 · Phase 2 —75 mg Q12W NCT04270760 · Phase 2 —75 mg Q12W NCT04270760 · Phase 2 1.7%10 mg Q12W NCT04270760 · Phase 2 —10 mg Q12W NCT04270760 · Phase 2 —10 mg Q12W NCT04270760 · Phase 2 16.7%675 mg NCT03626662 · Phase 1 · registry result, not featured evidence 50%225 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%225 mg NCT03626662 · Phase 1 · registry result, not featured evidence 66.7%75 mg NCT03626662 · Phase 1 · registry result, not featured evidence 33.3%75 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%30 mg NCT03626662 · Phase 1 · registry result, not featured evidence 33.3%9 mg NCT03626662 · Phase 1 · registry result, not featured evidence 11.1%9 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%3 mg NCT03626662 · Phase 1 · registry result, not featured evidence 8.3%High Dose NCT04987320 · Phase 1 · registry result, not featured evidence 0%Low Dose NCT04987320 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —225 mg Q12Wa NCT04270760 · Phase 2 show 22 more results—225 mg Q12W NCT04270760 · Phase 2 —225 mg Q12W NCT04270760 · Phase 2 —225 mg Q24W NCT04270760 · Phase 2 —225 mg Q24W NCT04270760 · Phase 2 —225 mg Q24W NCT04270760 · Phase 2 —75 mg Q12W NCT04270760 · Phase 2 —75 mg Q12W NCT04270760 · Phase 2 —75 mg Q12W NCT04270760 · Phase 2 —10 mg Q12W NCT04270760 · Phase 2 —10 mg Q12W NCT04270760 · Phase 2 —10 mg Q12W NCT04270760 · Phase 2 —675 mg NCT03626662 · Phase 1 · registry result, not featured evidence —225 mg NCT03626662 · Phase 1 · registry result, not featured evidence —225 mg NCT03626662 · Phase 1 · registry result, not featured evidence —75 mg NCT03626662 · Phase 1 · registry result, not featured evidence —75 mg NCT03626662 · Phase 1 · registry result, not featured evidence —30 mg NCT03626662 · Phase 1 · registry result, not featured evidence —9 mg NCT03626662 · Phase 1 · registry result, not featured evidence —9 mg NCT03626662 · Phase 1 · registry result, not featured evidence —3 mg NCT03626662 · Phase 1 · registry result, not featured evidence —High Dose NCT04987320 · Phase 1 · registry result, not featured evidence —Low Dose NCT04987320 · Phase 1 · registry result, not featured evidence |
| Serious AEs | —225 mg Q12Wa NCT04270760 · Phase 2 show 22 more results11.1%225 mg Q12W NCT04270760 · Phase 2 10.7%225 mg Q12W NCT04270760 · Phase 2 —225 mg Q24W NCT04270760 · Phase 2 9.1%225 mg Q24W NCT04270760 · Phase 2 7.3%225 mg Q24W NCT04270760 · Phase 2 —75 mg Q12W NCT04270760 · Phase 2 3.5%75 mg Q12W NCT04270760 · Phase 2 5.2%75 mg Q12W NCT04270760 · Phase 2 —10 mg Q12W NCT04270760 · Phase 2 7%10 mg Q12W NCT04270760 · Phase 2 5.2%10 mg Q12W NCT04270760 · Phase 2 0%675 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%225 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%225 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%75 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%75 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%30 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%9 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%9 mg NCT03626662 · Phase 1 · registry result, not featured evidence 0%3 mg NCT03626662 · Phase 1 · registry result, not featured evidence 8.3%High Dose NCT04987320 · Phase 1 · registry result, not featured evidence 8.3%Low Dose NCT04987320 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 225 mg Q12Wa covid-19 25.9% (placebo 18.9%) headache 3.7% (placebo 0%) immunisation reaction 3.7% (placebo 0%) NCT04270760 · Phase 2 show 18 more results225 mg Q12W back pain 12.5% (placebo 0%) covid-19 12.5% (placebo 18.9%) headache 10.7% (placebo 0%) NCT04270760 · Phase 2 225 mg Q24W covid-19 18.2% (placebo 18.9%) fall 3.6% (placebo 0%) nasopharyngitis 3.6% (placebo 0%) NCT04270760 · Phase 2 225 mg Q24W headache 10.9% (placebo 0%) injection site pain 9.1% (placebo 0%) covid-19 7.3% (placebo 18.9%) NCT04270760 · Phase 2 75 mg Q12W covid-19 19.3% (placebo 18.9%) urinary tract infection 7% (placebo 0%) anaemia 3.5% (placebo 1.9%) NCT04270760 · Phase 2 75 mg Q12W covid-19 13.8% (placebo 18.9%) fatigue 13.8% (placebo 1.9%) headache 12.1% (placebo 0%) NCT04270760 · Phase 2 10 mg Q12W covid-19 14% (placebo 18.9%) back pain 5.3% (placebo 0%) nasopharyngitis 5.3% (placebo 0%) NCT04270760 · Phase 2 10 mg Q12W immunisation reaction 13.8% (placebo 0%) back pain 10.3% (placebo 0%) fatigue 10.3% (placebo 1.9%) NCT04270760 · Phase 2 675 mg diabetes mellitus 16.7% (placebo 0%) diastolic hypertension 16.7% (placebo 0%) dyspnoea 16.7% (placebo 0%) NCT03626662 · Phase 1 · registry result, not featured evidence 225 mg abdominal discomfort 0% (placebo 0%) abdominoplasty 0% (placebo 0%) actinic keratosis 0% (placebo 0%) NCT03626662 · Phase 1 · registry result, not featured evidence 225 mg urinary tract infection 40% (placebo 0%) abdominal discomfort 20% (placebo 0%) covid-19 20% (placebo 0%) NCT03626662 · Phase 1 · registry result, not featured evidence 75 mg gastrooesophageal reflux disease 16.7% (placebo 0%) abdominal discomfort 0% (placebo 0%) abdominoplasty 0% (placebo 0%) NCT03626662 · Phase 1 · registry result, not featured evidence 75 mg headache 22.2% (placebo 10%) actinic keratosis 11.1% (placebo 0%) arthralgia 11.1% (placebo 0%) NCT03626662 · Phase 1 · registry result, not featured evidence 30 mg upper respiratory tract infection 33.3% (placebo 10%) blood creatine phosphokinase increased 16.7% (placebo 10%) catheter site pain 16.7% (placebo 0%) NCT03626662 · Phase 1 · registry result, not featured evidence 9 mg back pain 16.7% (placebo 10%) ear injury 16.7% (placebo 0%) insomnia 16.7% (placebo 0%) NCT03626662 · Phase 1 · registry result, not featured evidence 9 mg headache 22.2% (placebo 10%) upper respiratory tract infection 22.2% (placebo 10%) animal scratch 11.1% (placebo 0%) NCT03626662 · Phase 1 · registry result, not featured evidence 3 mg upper respiratory tract infection 33.3% (placebo 10%) arthralgia 16.7% (placebo 0%) contusion 16.7% (placebo 0%) NCT03626662 · Phase 1 · registry result, not featured evidence High Dose covid-19 25% contusion 16.7% injection site erythema 16.7% NCT04987320 · Phase 1 · registry result, not featured evidence Low Dose diarrhoea 25% pyrexia 25% oropharyngeal pain 16.7% NCT04987320 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olpasiran
show 133 more results
show 7 more results
show 7 more results
show 125 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olpasiran's landscape · SYH2068's landscape